ECTRIMS 2015 round up
Source MS Trust
ECTRIMS (European Committee for Treatment and Research In Multiple Sclerosis) hosts the world’s largest conference devoted to basic and clinical research in MS.
This year’s meeting took place in Barcelona from 7-10 October and featured a wide range of presentations, posters and reports of new and on-going research. Read on.
Biogen says multiple sclerosis drug trial for Natalizumab was unsuccessful.
Biogen Inc. said Wednesday that a late-stage trial of a drug to treat of secondary progressive multiple sclerosis was unsuccessful. The trial of Natalizumab found that the drug was “well-tolerated” by patients but did not meet its primary and secondary endpoints. “While we’re disappointed with these results, we believe this research will provide the MS community important insights into this more advanced patient population,” said Alfred Sandrock, group senior vice president and chief medical officer at Biogen, in the press release. Shares of Biogen rose 10% Wednesday after the company beat third-quarter earnings expectations
Study on Biotin for Secondary and Primary Progressive Forms of Multiple Sclerosis
Want to take part in a clinical trial?
Note: For people with relapsing remitting MS or Secondary progressive MS only.
Want to take part in a clinical trial? In recognition of your time involved in this study you will receive £1,250 and all your travel needs will be organised by Trials4Us. BMSTC will also receive a donation.
Trials4Us are carrying out an important clinical trial of a new treatment for people with RFMS. This is a validation study to check that a particular imaging technique works.
There are no expected benefits to you from participation in this study, it is purely for research purposes. However, by taking part in this study, you may be helping future patients by contributing to medical knowledge about RFMS. Find out more here.
Christmas Lunch – 16th December
October 100 Club winners
That’s Oxford broadcast
Multiple Sclerosis Patient Survey
Invitation: Multiple Sclerosis Patient Survey
Opinion Health, an independent research agency based in London, is currently inviting people diagnosed with multiple sclerosis to take part in an online survey. This survey is designed to provide a better understanding of your experience of the treatment you are receiving as well as your treatment preferences.
The survey should take around 20 minutes to complete. As a token of our appreciation for your time and interest, you will receive a £15 Amazon Gift Card if you successfully complete the survey.
IMPORTANT: There are some interactive elements in the survey designed to make it more interesting for you. Therefore we would strongly recommend accessing and completing this survey via a desktop computer or a laptop.
Please let us know if this is a problem for you. One of our team will be more than happy to assist you.
Please click on the link below for more information:
http://survey.opinionhealth.co.uk/uc/8018L/?a=1&b=AN&c=AS&d=102
If you have any questions about this study, please feel free to contact us either by email on info@opinionhealth.com or by phone on 0207 486 6700.
Many thanks in advance,
OH Research Team
Opinion Health
11 Poland Street
London W1F 8QA
+44 (0)207-486-6700
—
About Opinion Health:
We are a healthcare research agency based in London. We are a member of the BHBIA (British Healthcare Business Intelligence Association), AQR (The Association for Qualitative Research), and EphMRA (European Pharmaceutical Market Research Association).
If you would rather not receive future e-mails of this sort from Opinion Health, please reply to us with “Unsubscribe” in the subject line.